Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Published

Journal Article

Some patients are unable to achieve and maintain an undetectable plasma HIV-1 RNA level with combination antiretroviral therapy (ART) and are therefore maintained on a partially suppressive regimen. To determine the immune consequences of continuing ART despite persistent viremia, we randomized 47 ART-treated individuals with low to moderate plasma HIV-1 RNA levels (200-9999 copies/ml) to either an immediate switch in therapy or a delayed switch (when plasma HIV-1 RNA became > or =10,000 copies/ml). After 48 weeks of follow-up, naive and memory CD4+ T cell percents were comparable in the two groups. The proportion of subjects with a lymphocyte proliferative response to Candida, Mycobacterium avium-intracellulare complex, or HIV-gag was also not significantly different at week 48. Delaying a treatment switch in patients with partial virologic suppression and stable CD4+ T cells does not have profound effects on immune parameters.

Full Text

Duke Authors

Cited Authors

  • Tenorio, AR; Jiang, H; Zheng, Y; Bastow, B; Kuritzkes, DR; Bartlett, JA; Deeks, SG; Landay, AL; Riddler, SA

Published Date

  • February 2009

Published In

Volume / Issue

  • 25 / 2

Start / End Page

  • 135 - 139

PubMed ID

  • 19239354

Pubmed Central ID

  • 19239354

Electronic International Standard Serial Number (EISSN)

  • 1931-8405

Digital Object Identifier (DOI)

  • 10.1089/aid.2008.0200

Language

  • eng

Conference Location

  • United States